C-08 Is Not The End Of Avastin’s Adjuvant Opportunity, Roche/Genentech Say

ORLANDO, Fla. - The failed C-08 trial does not signify the death knell of the adjuvant opportunity for Roche/Genentech's cancer drug Avastin, company executives assert

More from Archive

More from Pink Sheet